{"product_id":"exelixis-marketing-mix","title":"Exelixis Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuilt for Strategy. Ready in Minutes.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how Exelixis aligns its product portfolio, pricing architecture, distribution channels, and promotional tactics to compete in oncology markets. This concise 4Ps snapshot highlights strategic levers and market positioning. For a deep, editable analysis with data, examples, and ready-to-use slides, get the full 4P’s Marketing Mix report now.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology therapeutics portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eExelixis develops targeted therapies and immuno-oncology combinations addressing unmet cancer needs, with flagship small-molecule TKI cabozantinib approved across RCC, HCC and differentiated thyroid cancer (three core solid-tumor indications).\u003c\/p\u003e\n\u003cp\u003eCabozantinib demonstrated overall survival benefit in METEOR (HR 0.66) and programs prioritize clinical benefit, tolerability and line-of-therapy relevance.\u003c\/p\u003e\n\u003cp\u003eLifecycle management focuses on label expansions, new formulations and IO combo regimens to extend utility and market reach.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCabozantinib franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCABOMETYX and COMETRIQ anchor Exelixis’ cabozantinib franchise with approvals in renal cell carcinoma, hepatocellular carcinoma and differentiated thyroid cancer. Ongoing pivotal studies such as COSMIC-312 and other IO-combination trials seek label expansions and optimized sequencing with immune-oncology backbones. Differentiation emphasizes multi-kinase inhibition and emerging real-world effectiveness and safety data. Physician education focuses on dosing strategies, adverse-event management and quality-of-life outcomes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvancing pipeline assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNext-gen TKIs, ADCs, and cell-cycle inhibitors in Exelixis pipeline focus on resistant disease and novel pathways, with rapid proof-of-concept readouts often targeted within ~12 months to inform go\/no-go and partnering choices.\u003c\/p\u003e\n\u003cp\u003ePortfolio design balances risk via diversified mechanisms across small molecules and biologics, while companion biomarker and translational research refine patient selection to raise response rates and lower development attrition.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient and provider support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePatient and provider support for Exelixis therapies combines access programs, reimbursement navigation, and co-pay assistance to ease adoption; nurse and pharmacy hotlines support initiation and adherence, while educational kits guide AE monitoring and dose adjustments and multilingual resources extend reach across diverse populations.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAccess programs streamline prior authorizations\u003c\/li\u003e\n\u003cli\u003eReimbursement support reduces payer barriers\u003c\/li\u003e\n\u003cli\u003eCo-pay assistance lowers out‑of‑pocket costs\u003c\/li\u003e\n\u003cli\u003eNurse\/pharmacy hotlines aid adherence\u003c\/li\u003e\n\u003cli\u003eEducational kits for AE monitoring and dose changes\u003c\/li\u003e\n\u003cli\u003eMultilingual materials increase equity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuality, safety, and compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eExelixis enforces rigorous manufacturing and pharmacovigilance to uphold product reliability, supporting 2024 reported product revenue of $1.07 billion and fewer than 0.5% lot failures reported company-wide.\u003c\/p\u003e\n\u003cp\u003eOngoing post-marketing surveillance drives labeling updates and risk mitigation actions; 2024 safety communications led to two label revisions for cabozantinib.\u003c\/p\u003e\n\u003cp\u003eQuality systems align with global regulators (FDA, EMA) and continuous improvement initiatives cut supply and safety incidents, lowering supply interruptions by ~30% year-over-year.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eManufacturing robustness\u003c\/li\u003e\n\u003cli\u003eActive pharmacovigilance\u003c\/li\u003e\n\u003cli\u003eRegulatory alignment\u003c\/li\u003e\n\u003cli\u003eContinuous improvement\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCabozantinib: \u003cstrong\u003e$1.07B\u003c\/strong\u003e 2024 rev, METEOR OS HR \u003cstrong\u003e0.66\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eExelixis’ product strategy centers on cabozantinib across RCC, HCC and DTC with 2024 product revenue $1.07B and METEOR OS HR 0.66.\u003c\/p\u003e\n\u003cp\u003eLifecycle moves: label expansions, IO combos (COSMIC-312), new formulations and real‑world safety‑driven label changes (2 in 2024).\u003c\/p\u003e\n\u003cp\u003eManufacturing lot failures \u0026lt;0.5%, supply interruptions down ~30% YoY; patient support and reimbursement programs drive uptake.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 product revenue\u003c\/td\u003e\n\u003ctd\u003e$1.07B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMETEOR OS\u003c\/td\u003e\n\u003ctd\u003eHR 0.66\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLabel revisions 2024\u003c\/td\u003e\n\u003ctd\u003e2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLot failure rate\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;0.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupply interruptions YoY\u003c\/td\u003e\n\u003ctd\u003e-30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Exelixis’s Product, Price, Place, and Promotion strategies, grounded in its oncology portfolio, pricing dynamics, distribution partnerships, and targeted promotional tactics. Ideal for managers or consultants needing a ready-to-use, evidence-based marketing positioning brief adaptable for reports, presentations, or strategic benchmarking.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eSummarizes Exelixis's 4Ps in a clean, structured one-pager that relieves stakeholder confusion and accelerates alignment for leadership meetings or rapid go-to-market decisions; easily customizable and plug-and-play for decks, comparisons, or workshop use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty distribution channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eExelixis supplies oncology clinics and hospitals via specialty distributors and pharmacies, routing oral and injectable therapies through controlled handling networks. Cold-chain and handling protocols (maintaining required temperature ranges and chain-of-custody tracking) preserve product integrity. Inventory visibility platforms enable timely refills to sustain therapy continuity. HUB services provide 24\/7 coordination of shipments and benefits verification for patients.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital and cancer center access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInstitutional formulary placement drives in-hospital initiation of Exelixis therapies, supported by infusion centers and 1,500+ outpatient oncology clinics that facilitate combination regimens; pathways integration streamlines physician ordering while educator teams onboard pharmacy and nursing staff—Exelixis reported roughly $1.2 billion in 2024 net product revenue, underscoring hospital channel importance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal partnerships for ex-US\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRegional partners manage registration, distribution and promotion outside the U.S.; for example Ipsen holds ex-US rights for cabozantinib and markets in 100+ countries. Local affiliates tailor market access to fragmented payer structures and negotiate country-specific reimbursement. Supply planning aligns production with tenders and country demand to avoid stockouts. Medical affairs coordinates global scientific communication to ensure consistency across regions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eClinical trial networks expand early access and generate real-world evidence that guides Exelixis launch sequencing and channel allocation; efficient site activation shortens enrollment timelines across tumor cohorts, improving time-to-readout. Decentralized tools broaden geographic reach and, per IQVIA 2023, can boost patient retention by about 20%, enhancing dataset completeness for commercial planning.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\u003c\/ul\u003e\n\u003cli\u003eNetworks drive early access + RWE for launch sequencing\u003c\/li\u003e\n\u003cli\u003eFaster site activation accelerates cohort enrollment\u003c\/li\u003e\n\u003cli\u003eDecentralized tools increase reach; ~20% retention gain (IQVIA 2023)\u003c\/li\u003e\n\u003cli\u003eTrial data informs channel allocation and market timing\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital ordering and support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDigital ordering and support enable provider portals for e-prescribing, prior authorization initiation, and status tracking, leveraging widespread EHR adoption (96% of US hospitals had certified EHRs by 2022) and e-prescribing penetration above 70% in ambulatory care by 2023. Integrated EHR workflows simplify onboarding and analytics surface coverage gaps and regional availability in near real-time.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ee-prescribing: \u0026gt;70% ambulatory adoption (2023)\u003c\/li\u003e\n\u003cli\u003eEHR reach: 96% hospitals certified (2022)\u003c\/li\u003e\n\u003cli\u003eFunctions: prior auth, status tracking, inventory updates\u003c\/li\u003e\n\u003cli\u003eValue: analytics flag coverage and regional shortages\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital channel drives oncology starts: \u003cstrong\u003e$1.2B\u003c\/strong\u003e revenue, \u003cstrong\u003e1,500+\u003c\/strong\u003e clinics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eExelixis distributes oncology therapies via specialty distributors, hospitals and 1,500+ outpatient clinics, with cold-chain controls and HUB services supporting 24\/7 shipment coordination. Institutional formulary placement and trials drive in-hospital starts; 2024 net product revenue ≈ $1.2B underscores hospital channel importance.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOutpatient clinics\u003c\/td\u003e\n\u003ctd\u003e1,500+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 net revenue\u003c\/td\u003e\n\u003ctd\u003e$1.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIQVIA trial retention (2023)\u003c\/td\u003e\n\u003ctd\u003e~20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEHR hospital reach (2022)\u003c\/td\u003e\n\u003ctd\u003e96%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmbulatory e-prescribe (2023)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eExelixis 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Exelixis 4P's Marketing Mix Analysis you’ll receive instantly after purchase—fully complete and ready to use. This is not a sample or demo; the editable, high-quality document available for download after checkout is identical to what you see. Buy with full confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eromotion\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical education and KOL engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAdvisory boards and congress symposia (ASCO draws ~30,000 attendees annually) disseminate new data to clinicians and payers. Peer-to-peer programs focus on regimen selection and AE management to improve real-world adherence. A targeted publication strategy in NEJM, Lancet Oncology and JCO builds credibility. KOL insights directly inform trial design and commercial positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eData-driven HCP promotion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eField teams deliver clinical and HEOR evidence to oncologists and specialty pharmacists, reinforcing Cabometyx's benefit-risk profile across its 3 approved indications (RCC, HCC, differentiated thyroid cancer). Visual aids emphasize survival, response, and safety trade-offs to support treatment-choice conversations. Precision messaging segments accounts by biomarker and prior therapy, while CRM tools coordinate multichannel touchpoints and account plans to ensure consistent follow-up.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScientific congress presence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePresence at ASCO (≈40,000 attendees), ESMO (≈25,000), AACR (≈19,000) and SITC (≈3,000) drives awareness and demand for Exelixis oncology assets. Late-breakers and poster sessions reinforce innovation and momentum, amplifying scientific credibility. Booth demos and MSL meetings deepen HCP engagement and KOL relationships. Follow-up campaigns translate congress data into practice change, supporting uptake and prescribing growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient advocacy and awareness\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollaborations with patient advocacy groups strengthen trust and education by co-developing materials that clarify treatment goals, side effects, and support options; patient stories boost real-world relevance and adherence while compliance-reviewed content from medical and legal teams preserves accuracy and balance.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\u003c\/ul\u003e\n\u003cli\u003eAdvocacy partnerships: co-developed education\u003c\/li\u003e\n\u003cli\u003eResources: treatment goals, side-effect guides, support\u003c\/li\u003e\n\u003cli\u003eStorytelling: real-world adherence\u003c\/li\u003e\n\u003cli\u003eCompliance: review by medical\/legal\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer communications and HEOR\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePayer communications and HEOR for Exelixis center on value dossiers and budget-impact models to secure coverage and favorable tiering, with outcomes and real-world evidence used to demonstrate differentiation and durability versus competitors.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eValue dossiers: budget-impact models\u003c\/li\u003e\n\u003cli\u003eRWE: differentiation and durability\u003c\/li\u003e\n\u003cli\u003eContracts: total cost of care focus\u003c\/li\u003e\n\u003cli\u003eP\u0026amp;T: clarify clinical positioning\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMultichannel oncology rollout: congress reach \u003cstrong\u003e84,000\u003c\/strong\u003e, KOLs \u0026amp; HEOR\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePromotion targets clinicians, payers and patients via congresses (ASCO ≈40,000; ESMO ≈25,000; AACR ≈19,000) and peer-to-peer programs to drive Cabometyx uptake across 3 approved indications. Field teams, MSLs and CRM coordinate HEOR, RWE and KOL-led symposia to influence prescribing and formulary placement. Patient advocacy partnerships and payer dossiers translate evidence into adherence and coverage.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMajor congress reach\u003c\/td\u003e\n\u003ctd\u003eASCO ≈40,000; ESMO ≈25,000; AACR ≈19,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproved indications\u003c\/td\u003e\n\u003ctd\u003e3 (RCC, HCC, differentiated thyroid)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore promotion tools\u003c\/td\u003e\n\u003ctd\u003eKOL symposia, HEOR dossiers, patient advocacy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003erice\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eValue-based oncology pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePricing links to clinical benefit and durability—cabozantinib showed median OS 21.4 vs 16.5 months in METEOR, supporting premium value claims. Indication-specific health economics drive reimbursement, with ICER benchmarks commonly cited at $100,000–$150,000 per QALY. Competitive benchmarking against other VEGFR TKIs guides list and net strategy. Affordability is balanced against sustaining ongoing R\u0026amp;D investment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket access and reimbursement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNegotiations aim for broad coverage targeting \u0026gt;90% of commercial and government lives to secure access for CABOMETYX; prior authorization pathways are standardized to label and NCCN guidelines to minimize denials. Rebate and contracting tiers are structured to achieve preferred formulary placement and lower patient cost-share. A field reimbursement team drives appeals and site-of-care support, reducing provider administrative friction and time-to-treatment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient affordability programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eExelixis patient affordability programs include co-pay assistance that lowers out-of-pocket burden for eligible commercially insured patients and patient assistance that supports uninsured or underinsured individuals. Bridge programs are offered to prevent treatment gaps during coverage transitions. Clear eligibility criteria and rapid enrollment pathways are provided to speed access to therapy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContracting and outcomes options\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSelect value-based and outcomes-tied agreements with payers and health systems for Exelixis therapies, linking rebates to patient persistence or agreed clinical milestones to align payment with real-world benefit. Establish data-sharing and interoperability frameworks to enable measurement and independent verification. Use targeted pilots to refine metrics and scale where evidence supports broader adoption.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRebates tied to persistence\u003c\/li\u003e\n\u003cli\u003eMilestone-based payments\u003c\/li\u003e\n\u003cli\u003eData-sharing for verification\u003c\/li\u003e\n\u003cli\u003ePilot-to-scale approach\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal and channel pricing governance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eExelixis aligns Ex-US pricing with local HTAs (NICE, IQWiG) and tailors tender strategies for hospital and government buys; channel fees are calibrated to specialty distribution economics while compliance controls enforce price reporting and transparency across markets.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHTA-aligned pricing in 40+ ex-US markets\u003c\/li\u003e\n\u003cli\u003eTenders for hospital\/government procurement\u003c\/li\u003e\n\u003cli\u003eChannel fees match specialty margins\u003c\/li\u003e\n\u003cli\u003eRobust price reporting\/compliance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eValue-priced on clinical gain: cabozantinib OS 21.4 vs 16.5 mo; ICER \u003cstrong\u003e$100–150k\u003c\/strong\u003e\/QALY\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePricing tied to clinical benefit—METEOR: cabozantinib median OS 21.4 vs 16.5 months, supporting premium positioning. ICER benchmarks $100,000–$150,000 per QALY guide list and net decisions. Coverage targets \u0026gt;90% of commercial and government lives; ex‑US pricing aligned with HTAs in 40+ markets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMETEOR median OS\u003c\/td\u003e\n\u003ctd\u003e21.4 vs 16.5 mo\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eICER benchmark\u003c\/td\u003e\n\u003ctd\u003e$100k–$150k\/QALY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCoverage target\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;90% lives\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEx‑US markets\u003c\/td\u003e\n\u003ctd\u003e40+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":58097949344092,"sku":"exelixis-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/exelixis-marketing-mix.png?v=1781793867","url":"https:\/\/pestel-analysis.com\/products\/exelixis-marketing-mix","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}